Biogen (BIIB) Receivables - Other (2009 - 2024)

Biogen has reported Receivables - Other for 10 years, with the latest figure at $82.3 million in Q3 2024.

• On a quarterly basis, Receivables - Other fell 94.15% year-over-year to $82.3 million in Q3 2024; TTM through Sep 2024 was $82.3 million, a 94.15% decrease from a year earlier, with the FY2023 full-year figure at $117.5 million, up 5775.0% from the prior year.
• Receivables - Other was $82.3 million for Q3 2024 at Biogen, up from $77.4 million in the prior quarter.
• The five-year high for Receivables - Other was $1.4 billion in Q3 2023, with the low at $3.8 million in Q1 2020.
• Average Receivables - Other over 5 years is $316.4 million, with a median of $99.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other plunged 98.44% in 2023, then soared 1157.14% in 2024.
• Over 5 years, Receivables - Other stood at $151.1 million in 2020, then surged by 88.88% to $285.4 million in 2021, then jumped by 215.35% to $900.0 million in 2022, then tumbled by 86.94% to $117.5 million in 2023, then retreated by 29.96% to $82.3 million in 2024.
• The last three Receivables - Other figures came in at $82.3 million (Q3 2024), $77.4 million (Q2 2024), and $79.2 million (Q1 2024), per Business Quant data.